CR Double-Crane(SH:600062) Xin Lang Cai Jing·2025-10-20 09:26Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiary, Beijing Wanhui Double Crane Pharmaceutical Co., Ltd., received the drug registration certificate for Alfacalcidol soft capsules from the National Medical Products Administration, indicating a significant advancement in the company's product portfolio [1] Group 1: Product Development - The drug is indicated for the treatment of calcium metabolism disorders caused by insufficient endogenous 125-dihydroxyvitamin D3, including conditions such as renal osteodystrophy and vitamin D-dependent rickets [1] - The company initiated the development of this generic drug in August 2022 and submitted the marketing authorization application on June 18, 2024, which was accepted on June 25, 2024, and approved for market launch on October 14, 2025 [1] - Cumulative R&D investment for this drug reached 4.9302 million RMB as of the announcement date [1]